[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ureteroscopy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ureteroscopy":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,59,92,122,144,175,208],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100645126","access-sheaths-with-aspiration-for-renal-retrograde-surgery-randomized-comparative-outcomes-100645126",false,"NCT07678255","Access Sheaths With Aspiration for Renal RetrOgrade Surgery, Randomized CompArative Outcomes","ACCESS SHEATHS WITH ASPIRATION FOR RETROGRADE RENAL SURGERY, RANDOMIZED COMPARATIVE OUTCOMES","ARROCA01","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of intrarenal lithiasis with maximum stone diameter of 1-3 cm on preoperative non-contrast abdomino-pelvic CT scan\n* Candidate for treatment by flexible ureteroscopy (RIRS) as indicated by the treating urologist\n* Attended at the Department of Urology, Hospital Universitario Virgen del Rocío (Seville, Spain)\n* Willing and able to provide written informed consent\n* Able to comply with the study follow-up schedule (CT scan at 1 and 3 months post-intervention)\n\nExclusion Criteria:\n\n* Active urinary tract infection or urosepsis at the time of the planned intervention\n* Known ureteral stricture precluding passage of a ureteral access sheath\n* Pregnancy\n* Prior urinary diversion incompatible with transurethral access (e.g., urinary conduit, neobladder)\n* Bleeding disorder or anticoagulant\u002Fantiplatelet therapy that cannot be safely interrupted perioperatively\n* Stone diameter \\\u003C1 cm or \\>3 cm on preoperative CT\n* Inability to provide informed consent (cognitive impairment, language barrier without interpreter availability)\n* Simultaneous participation in another clinical trial that could interfere with the outcomes of this study","ALL","18 Years",{"count":20,"type":21},156,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether the ClearPetra ureteral access sheath (Coloplast) is more effective than the Navigator ureteral access sheath (Boston Scientific) in treating intrarenal kidney stones of 1-3 cm in adult patients undergoing flexible ureteroscopy (RIRS). The main questions it aims to answer are:\n\nDoes ClearPetra achieve a higher stone-free rate at 1 month post-intervention compared to Navigator, as assessed by non-contrast abdominal-pelvic CT scan?\n\nDoes ClearPetra reduce total surgical time compared to Navigator?\n\nDoes ClearPetra lower the retreatment rate at 3 months compared to Navigator?\n\nDoes ClearPetra present a rate of clinically significant complications (Clavien-Dindo ≥ II) that is lower than or similar to Navigator?\n\nResearchers will compare flexible ureteroscopy using the ClearPetra vacuum-assisted flexible ureteral access sheath to flexible ureteroscopy using the Navigator standard rigid ureteral access sheath, to see if ClearPetra leads to higher stone clearance rates while maintaining a comparable safety profile.\n\nParticipants will:\n\nUndergo flexible ureteroscopy (RIRS) using one of two randomly assigned ureteral access sheaths (ClearPetra or Navigator), determined by computer-generated randomization immediately before surgery\n\nHave a non-contrast abdominal-pelvic CT scan at 1 month post-intervention to assess stone-free status\n\nHave a non-contrast abdominal-pelvic CT scan at 3 months post-intervention to evaluate residual fragments and the need for retreatment\n\nAttend follow-up visits at 1 month and 3 months post-surgery for clinical assessment and complication recording\n\nThe study will be conducted at the Urology Department of Hospital Universitario Virgen del Rocío (Seville, Spain), a tertiary reference centre. A total of 156 patients will be randomized in a 1:1 ratio (78 per group), with pre-defined subgroup analyses stratified by stone size (1-2 cm vs. \\>2 cm). The outcome assessor evaluating CT images for stone-free rate will be blinded to treatment allocation (single-blind).",[27,28,29,30],"Urolithiasis","Nephrolithiasis","Kidney Calculi","Ureteroscopy",[32,33,34,35,36,37,38,39,40,41,42,43,44,45],"Flexible ureteroscopy","Retrograde intrarenal surgery","RIRS","Ureteral access sheath","ClearPetra","Navigator","Stone-free rate","Laser lithotripsy","Intrarenal lithiasis","Vacuum-assisted sheath","Clavien-Dindo","Stone fragmentation","Endourology","Urinary tract calculi","NOT_YET_RECRUITING","2026-06-25",{"date":49,"type":50},"2026-07-01","ACTUAL",{"date":52,"type":21},"2026-09-15",{"date":54,"type":21},"2030-05",{"name":56,"class":57},"Hospitales Universitarios Virgen del Rocío","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":70,"briefSummary":72,"conditions":73,"keywords":78,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100642199","phase-3-assessing-suzetrigine-for-pain-reduction-following-ureteroscopic-surgery-100642199","NCT07654296","Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery","Multimodal Analgesia Pathway Assessing Role of Suzetrigine for the Reduction of Opioid Use Following Ureteroscopic Surgery","Inclusion Criteria:\n\n* Patients undergoing ureteroscopy between ages 21 to 80 at BWFH (Brigham \\& Women's Faulkner Hospital) by one of the department's high volume endoscopic surgeons. Patient who are or not pre-stented prior to surgery will be included (these will be assessed via stratification within a secondary analysis).\n* Patients able to consent for their own medical care (i.e. consent able to be obtained directly from patient and does not require a healthcare proxy or guardian)\n\nExclusion Criteria:\n\n* Regular opioid use prior to surgery or significant substance abuse concerns.\n* Inability of patient to provide their own consent (i.e. lack capacity).","21 Years","80 Years",{"count":69,"type":21},100,[71],"PHASE3","Urologic surgery has advanced with new technologies to allow less invasive management of common afflictions such as kidney stones, these procedures are notoriously painful as the ureter must be dilated to accommodate any instruments, and a ureteral stent is often left following surgery to allow for adequate healing. Unfortunately, stents are poorly tolerated by a significant number of patients, with up to 100% complaining of bothersome pain and 10% of patients with unplanned healthcare visits. Further complicating kidney stone management is the frequency of concurrent chronic kidney disease (CKD) or acute kidney injury (AKI) that prohibits many patients from taking NSAIDs which limits pain management options. There is now a push to treat these patients with multimodal analgesia to provide better care and reduce opioid use. Suzetrigine is a new a first-in-class selective inhibitor of the NaV1.8 sodium channel that functions as a non-opioid analgesic developed to treat acute pain and neuropathic pain. This study assesses the addition of suzetrigine to standard-of-care multimodal analgesia. We hypothesize a demonstrated decrease in opioid use, decrease Emergency Room visits within 30 days, decrease the number of unplanned care encounters.",[74,75,30,76,77],"Opioid Consumption, Postoperative","Multimodal Analgesia","Ureteral Stents","Ureteral Stent-Related Symptoms",[75,79,80,81],"Postoperative Opioid Consumption","ureteroscopy","ureteral stents","2026-06-12",{"date":84,"type":50},"2026-06-17",{"date":86,"type":21},"2026-08-01",{"date":88,"type":21},"2027-03-31",{"name":90,"class":57},"Brigham and Women's Hospital",2,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":105,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":58},"100613390","effects-of-virtual-reality-and-stress-ball-on-fear-pain-anxiety-and-satisfaction-in-ureterorenoscopy-patients-100613390","NCT07265960","Effects of Virtual Reality and Stress Ball on Fear, Pain, Anxiety, and Satisfaction in Ureterorenoscopy Patients","Effect of Virtual Reality and Stress Ball Interventions on Procedure-Related Fear, Pain, Anxiety, and Patient Satisfaction in Patients Undergoing Ureterorenoscopy","Inclusion Criteria:\n\n* • Aged 18 years or older,\n\n  * Scheduled for ureteroscopy (URS),\n  * Fully conscious, oriented, and cooperative,\n  * Provided written informed consent to participate in the study,\n  * Able to speak and understand Turkish,\n  * Without visual or hearing impairments,\n  * No prior experience with virtual reality (VR),\n  * Without any mental health disorders.\n\nExclusion Criteria:\n\n* Those who do not wish to participate or who wish to withdraw from the study, • Patients with chronic pain.",true,{"count":101,"type":21},90,[24],"This study aimed to determine the effects of virtual reality and stress ball interventions on procedure-related fear, anxiety, and patient satisfaction in patients undergoing ureterorenoscopy. The study is a prospective, randomized controlled clinical trial. The sample size was calculated to ensure sufficient statistical power to detect an effect size of Cohen's f = 0.333, considering α = 0.05, power (1-β) = 0.80, and number of groups = 3, resulting in 30 participants per group, for a total of 90 patients undergoing ureterorenoscopy.\n\nData will be collected using the \"Demographic Information Form,\" \"State Anxiety Inventory,\" \"Procedure-Related Fear Scale,\" \"Visual Analog Scale,\" and \"Newcastle Satisfaction with Nursing Care Scale.\" Upon admission to the clinic for the procedure, all patients will complete the \"Demographic Information Form,\" \"State Anxiety Inventory,\" and \"Procedure-Related Fear Scale\" prior to the surgical intervention.\n\nPatients in the virtual reality group will view nature scenes with relaxing music via a virtual reality headset in the clinic, with the sound level adjusted according to the patient's preference. Patients in the stress ball group will be instructed to squeeze the ball up to five counts every three counts. The control group will receive the routine pre-procedure procedures and standard care in the clinic.\n\nAfter the procedure, when patients return to the clinic (and are in bed), the \"State Anxiety Inventory,\" \"Visual Analog Scale,\" and \"Newcastle Satisfaction with Nursing Care Scale\" will be administered. Data analysis will include descriptive statistics and appropriate parametric or non-parametric tests (t-test, Mann-Whitney U, Kruskal-Wallis). A p-value of \\\u003C0.05 will be considered statistically significant in comparisons.",[30],[106,107,108,109,110,111],"Virtual reality","Stress ball","Anxiety","Pain","Patient satisfaction","Nursing","RECRUITING","2026-06-07",{"date":115,"type":50},"2026-06-09",{"date":117,"type":50},"2026-02-02",{"date":119,"type":21},"2026-12-15",{"name":121,"class":57},"Tarsus University",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":58},"100610130","phase-4-a-study-of-corticosteroid-on-postoperative-pain-after-ureteroscopy-for-urinary-calculi-100610130","NCT07223580","A Study Of Corticosteroid On Postoperative Pain After Ureteroscopy For Urinary Calculi","Evaluating The Role Of Corticosteroids In Post-Ureteroscopy Recovery For Urinary Calculi","Inclusion Criteria:\n\n* Patients who are diagnosed with kidney or ureteral stones confirmed on imaging (CT of the abdomen or pelvis) and who elect for definitive treatment via ureteroscopy with placement of ureteral stent.\n* Age 18 years or older\n* Patients of either gender\n* Patients of all ethnic backgrounds\n* Cable of giving informed consent\n* Capable and willing to fulfill the requirements of the study.\n\nExclusion Criteria:\n\n* History of chronic pain\n* Chronic use of opioids or other pain medication (\\>12 weeks)\n* Known allergies to corticosteroids.\n* Known or suspected pregnancy\n* Inability to give informed consent or unable to meet requirements of the study for any reason.\n* Bilateral ureteroscopy\n* Current Corticosteroid Use\n* Diabetic patients who are insulin dependent",{"count":101,"type":21},[131],"PHASE4","The purpose of this research is to evaluate if corticosteroid (prednisone) after ureteroscopy and placement of the stent will help alleviate postoperative pain control in addition to other normal postoperative pain medications",[30,134],"Post Operative Pain","2026-01-30",{"date":137,"type":50},"2026-02-03",{"date":139,"type":50},"2026-01-23",{"date":141,"type":21},"2027-12-01",{"name":143,"class":57},"Mayo Clinic",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":159,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100606915","clinical-trial-of-visor-vs-furs-for-upper-urinary-tract-stone-100606915","NCT07181759","Clinical Trial of VISOR vs fURS for Upper Urinary Tract Stone","Prospective Randomized Controlled Clinical Trial on the Treatment of Upper Urinary Tract Stones With VISOR and fURS","VISOR","Inclusion Criteria:\n\n* Patients with upper urinary tract stones and a cumulative stone diameter ≤3 cm;\n* Patients scheduled to undergo \"flexible ureteroscopic holmium laser lithotripsy\";\n* Age ≥18 years;\n* Patients without psychiatric disorders or language dysfunction, capable of understanding the study and providing informed consent.\n\nExclusion Criteria:\n\n* Patients requiring bilateral lithotripsy in a single-stage ureteroscopic procedure;\n* Ipsilateral hydronephrosis with \\>4 cm renal pelvic separation;\n* Patients with a history of open or laparoscopic renal and\u002For ureteral surgery;\n* Fever (body temperature ≥38°C) due to urinary tract infection or other causes within one week prior to surgery;\n* Pregnant women;\n* Patients with severe systemic diseases, cardiac diseases, pulmonary insufficiency, or vital organ failure unable to tolerate anesthesia or surgery (ASA score ≥3);\n* Patients with anatomical abnormalities such as polycystic kidney, horseshoe kidney, or ectopic kidney;\n* Patients with coagulation disorders (e.g., INR \\>2.0 or platelet count \\\u003C80×10⁹\u002FL);\n* Patients currently participating in other device or drug clinical trials;\n* Patients deemed ineligible for the trial by the investigator.",{"count":69,"type":21},[24],"This prospective randomized controlled clinical study aims to evaluate the safety and efficacy of a novel Vortex Intelligence Stone Optimized Removal (VISOR,The experimental group) system compared to a single-use ureterorenoscope (the control) for treating upper urinary tract stones.\n\nA total of 100 patients with upper urinary tract stones (cumulative stone diameter ≤3 cm) will be enrolled and randomly assigned in a 1:1 ratio to either the experimental group (n=50) or the control group (n=50). The experimental group will undergo surgery using the innovative system, which integrates irrigation-suction, pressure monitoring-regulation, and lithotripsy-evacuation functions. The control group will be treated with a conventional single-use ureterorenoscope.\n\nThe primary outcome measure is the immediate stone-free rate (SFR), defined as the proportion of patients with residual fragments \\\u003C4 mm on renal non-contrast computed tomography (NCCT) performed within 24 hours postoperatively. Key secondary endpoints include the SFR at 3 months, operative and lithotripsy times, total laser energy used, intraoperative ureteral injury (Traxer grading), postoperative pain scores, incidence of fever (\\>38.0°C), and overall complication rates (Clavien-Dindo classification).\n\nPatient follow-up assessments will be conducted at 24 hours, 21±7 days, and 90±14 days post-surgery to monitor stone clearance, complications, and recovery. This study seeks to determine if the novel system offers superior stone clearance while maintaining a safe renal pelvic pressure profile, potentially improving outcomes for patients with larger renal stones treated ureteroscopically.",[156,30,157,158],"Urolithiasis, Calcium Oxalate","Therapeutic Irrigation","Intraoperative Complications",[160,161,162,163,164,150,165],"Ureterorenoscopy","Upper urinary tract calculi","Intrarenal pressure","Stone-free rate (SFR)","Lithotripsy","Vortex intelligence Stone Optimized Removal(VISOR）","2025-09-12",{"date":168,"type":50},"2025-09-18",{"date":170,"type":21},"2025-09-20",{"date":172,"type":21},"2026-12-31",{"name":174,"class":57},"Ningbo No. 1 Hospital",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":58},"100552180","comparison-between-ureterorenoscopy-with-lithotripsy-alone-versus-combination-with-hydrogel-for-kidney-stone-removal-100552180","NCT06469736","Comparison Between Ureterorenoscopy With Lithotripsy Alone Versus Combination With Hydrogel for Kidney Stone Removal","Standard of Care Ureterorenoscopy With Lithotripsy Versus in Combination With the Hydrogel Method for Kidney Stone Removal: An Open, Randomized, Monocentric Study","Inclusion Criteria:\n\n* Male or female subjects aged ≥ 18 years\n* Evidence of nephrolithiasis on presentation of a preoperative computer tomography (CT) scan not older than 6 months\n* Minimum size of the kidney stones defined as \\>10mm in the longest axis in the preoperative CT.\n* Ability to read, write and speak German\n* Women of childbearing age must have a negative serum pregnancy test at the start of the study.\n* Submission of a personally signed and dated informed consent form stating that the subject has been informed of all relevant aspects of the study prior to any trial-related activity and that all information has been understood\n\nExclusion Criteria:\n\n* Participation in another clinical trial for kidney stone removal in the last 6 months\n* Subjects with gastrointestinal cancer who have not been in remission for at least 2 years\n* Subjects with a single kidney, horseshoe kidney or other anatomical abnormalities that may increase the risk of surgery for the subject\n* Subjects with untreated ureteral stenosis or renal stenosis and narrow ureteropelvic junction\u002Fureterovesical junction\n* Subjects with known impaired renal function from stage IV or known dialysis\n* Subjects with chronic hydronephrosis not associated with nephrolithiasis\n* Subjects with the following known or suspected diseases: Coagulation disorders, untreated urinary tract infections, renal disease sepsis and marked prostatic hyperplasia\n* Subjects with any other disease or condition that, in the opinion of the investigator, could interfere with the purpose of the study (e.g. bleeding that restricts vision in the kidney, problems in the renal tubular system)\n* Breastfeeding or pregnant women\n* Subjects who may be part of a vulnerable group (e.g. prisoners or developmentally delayed adults)",{"count":183,"type":21},120,[24],"The incidence of kidney stones (urolithiasis) has surged in both developing and developed countries, affecting approximately 15% of the global population. From 2010 to 2019, diagnoses of kidney and ureteral stones rose by 8% in Germany, 26% in France, and 15% in England. Correspondingly, the number of surgical stone removal procedures increased by 3%, 38%, and 18%, respectively. Common treatments include extracorporeal shock wave lithotripsy (ESWL), ureterorenoscopy (URS) with lithotripsy, and percutaneous nephrolithotomy (PCNL).\n\nURS, depending on stone size, has become a preferred method due to advancements in intraoperative imaging and laser technology. Despite these improvements, small fragments often remain post-intervention, leading to recurrent stones. Complete removal of all fragments is crucial to significantly reduce recurrence rates. Current literature suggests a high recurrence rate with residual fragments, impacting healthcare costs and patient quality of life.\n\nA key objective in endourological research is optimizing the stone clearance rate. Techniques like coagulum lithotomy and the autologous blood clot technique have been developed to enhance residual stone removal after laser fragmentation. These methods benefit selected patients but are not widely adopted due to complications such as reduced intraoperative visibility and long coagulum formation times.\n\nRecently, a two-component hydrogel system called mediNiK® (Purenum GmbH, Germany) was developed. This biocompatible gel can be applied through an endoscope after stone fragmentation and large fragment retrieval to embed smaller fragments and dust, forming a removable conglomerate. MediNiK® has demonstrated effectiveness in embedding and removing stone residues and is already in clinical use in Europe, showing potential for optimizing stone removal.\n\nA multicenter study has assessed the safety and tolerability of mediNiK® in standard URS (Open, randomized, multicentre study to evaluate the safety, tolerability, and performance of mediNiK® compared to standard treatment in kidney stone removal - DRKS00030532). Results indicate the gel is safe and tolerable. However, further data from larger cohorts and comparisons with conventional URS are necessary before widespread adoption of mediNiK®.",[28,187,30],"Lithotripsy, Laser",[189,190,191,192,193,194,195,196,197,198],"Hydrogel","MediNiK","Hydrogel methode","Stone Free Rate","Zero Residual Fragments","URS","Dusting","Stone free","Thulium","Kidneystones","2025-09-02",{"date":201,"type":50},"2025-09-09",{"date":203,"type":50},"2024-07-01",{"date":205,"type":21},"2026-07-30",{"name":207,"class":57},"Technical University of Munich",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":225,"leadSponsor":227,"locationsCount":58},"100574361","effect-of-laughter-yoga-on-surgical-fear-and-anxiety-in-patients-applied-before-ureteroscopy-100574361","NCT06758284","Effect of Laughter Yoga on Surgical Fear and Anxiety in Patients Applied Before Ureteroscopy","Effect of Laughter Yoga on Surgical Fear and Anxiety in Patients Applied Before Ureteroscopy: a Randomized Controlled Trial","Inclusion Criteria:\n\nIt will be applied to patients who agree to participate in the study, are scheduled to undergo ureteroscopy in a urological surgery clinic, have no hearing or vision problems, are over the age of 18, understand and speak Turkish, are literate, and can communicate.\n\nExclusion Criteria:\n\nPatients with mental retardation and any psychiatric disorder, alcohol or drug addiction, hypertension or heart disease, hernia, glaucoma will be excluded.",{"count":216,"type":21},92,[24],"Surgical fear is a situation where a person experiences excessive fear of surgical procedures. This fear can negatively affect the person's normal life and is usually more intense in the pre-operative period. The causes of surgical fear include factors such as previous negative surgical experiences, lack of sufficient information, post-operative pain and complications. In addition, factors such as age, gender, and level of education can also affect fear. This fear can lead to physical and psychological problems along with stress; symptoms such as increased heart rate, dizziness, and muscle tension can be seen. Methods such as cognitive-behavioral therapy, meditation, and hypnosis can be used in the treatment of surgical fear. In addition, anxiety can also arise from thinking about the surgical procedure, post-operative complications, fear of anesthesia, or pain. High-risk surgeries and past negative experiences can increase anxiety. High anxiety before surgery can lead to psychological and physical problems. Nurses should offer anxiety-reducing techniques (breathing exercises, relaxation) by taking into account the needs of patients. In addition, having relatives with the patient can help relieve anxiety. Laughter yoga is considered an effective complementary therapy to reduce surgical fear and anxiety. Developed in India in 1995, this method involves simulating laughter with yoga breathing techniques. Laughter yoga relaxes muscles, increases pain threshold, and improves overall psychological well-being. This study aims to evaluate the effects of laughter yoga on patients undergoing ureteroscopy.",[30,220],"Kidney Stones","2024-12-26",{"date":223,"type":50},"2025-01-03",{"date":203,"type":50},{"date":226,"type":21},"2024-12-30",{"name":228,"class":57},"Kocaeli University"]